LEO III Fund acquires PronoKal Group from Nestlé Health Science to drive innovation and global growth in ketogenic nutrition

Munich/Barcelona, July 31, 2025 – Lenbach Equity Opportunities III. GmbH & Co. KG ("LEO III Fund"), a private equity fund advised by the DUBAG Group and specialized in corporate carve-outs, has successfully completed the acquisition of PronoKal Group from Nestlé Health Science.

PronoKal, a pioneer in scientifically backed ketogenic diet programs, will now operate as an independent company. Under the ownership of LEO III Fund, the company is positioned to accelerate innovation and capture growth opportunities in the rapidly expanding ketogenic nutrition market.

Accelerating innovation and growth in ketogenic nutrition

With the support and long-term perspective of LEO III Fund, PronoKal is set to elevate its role as an innovative and internationally recognized leader in ketogenic nutrition. Building on its strong scientific foundation, the company will intensify research and development, broaden its innovative product portfolio, and expand the reach of its medically supervised programs.

PronoKal's approach combines cutting-edge nutritional science with personalized coaching and premium-quality products, delivering sustainable health outcomes for patients. By strengthening collaborations with healthcare professionals and expanding into new markets, the company aims to set new standards and solidify its leadership position in this dynamic segment.

Joan Mestres, Managing Director of PronoKal:

"This marks an exciting new chapter for PronoKal. I want to thank Nestlé Health Science for their support over the last 3 years, which have helped us build a strong foundation. Joining forces with the LEO III Fund opens up a world of opportunity to accelerate innovation, expand our reach, and continue delivering life-changing results to our patients. We are energized by the possibilities ahead and fully committed to driving meaningful impact in health and wellness worldwide."

Dr. Michael Schumann, CEO of DUBAG Group, commented:

"We are proud to have acquired PronoKal from Nestlé Health Science. PronoKal combines a unique scientific approach with strong market potential. Together with the management team, we will drive innovation and support the company's growth journey, positioning PronoKal as the global leader in ketogenic nutrition."

Sandra Palau, BEO of Nestlé Health Science Iberia, commented:

"I want to thank the PronoKal teams for their strong contributions to Nestlé Health Science and wish them ongoing success. At Nestlé Health Science, we will continue supporting people on weight loss journeys with nutritional solutions."

About PronoKal Group

PronoKal is a pioneer in ketogenic diet programs, offering medically supervised solutions and personalized coaching to support weight management and metabolic health. Headquartered in Barcelona, the company provides a comprehensive portfolio of science-based products and services designed to improve health outcomes and quality of life.

For more information, visit www.pronokal.com.

About Nestlé Health Science

Nestlé Health Science, a leader in the science of nutrition, is a globally managed business unit of Nestlé. We are committed to redefining the management of health, offering an extensive portfolio of science-based consumer health, medical nutrition, pharmaceutical therapies, and vitamin and supplement brands. Our extensive research network provides the foundation for products that empower healthier lives through nutrition. Headquartered in Switzerland, we have more than 11,000 employees in 56 countries.

Find out more about Nestlé Health Science at www.nestlehealthscience.com.

About DUBAG Group and LEO III. Fund

Founded in 2009 and based in Munich, the DUBAG Group is a rapidly growing investment firm managing the private equity fund Lenbach Equity Opportunities III. GmbH & Co. KG ("LEO III Fund"). The fund invests in mid-cap companies in special situations such as corporate carve-outs, turnarounds, succession solutions in family-owned businesses, complex financing structures, and tail-end situations for financial investors. The LEO III Fund follows a pan-European investment strategy, with a particular focus on the DACH region, Italy, and Spain.

For further information, please contact:

Dr. Michael Schumann
CEO

DUBAG Group
Thomas-Wimmer-Ring 1,
80539 Munich

T. +49 89 45 209 45 – 0
E. contact@dubag.eu